2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Jeffrey S. Weber, MD, PhD, discusses emerging therapies in melanoma.
Jeffrey S. Weber, MD, PhD, deputy director of NYU Langone Health’s Perlmutter Cancer Center; Laura and Isaac Perlmutter Professor of Oncology in the Department of Medicine at NYU Grossman School of Medicine; and the 2016 Giant of Cancer Care® in Melanoma, discusses emerging therapies in melanoma.
In the future, the field can expect to see novel agents used in combination with tumor-infiltrating lymphocyte therapy, as well as novel checkpoints such as sialic acid-binding immunoglobulin-type lectins, says Weber.
Moreover, research evaluating bispecific molecules targeting PD-1, CTLA-4, inducible T-cell costimulator, and OX40 is ongoing, explains Weber.
Additionally, triplet regimens with immunotherapy may be evaluated as a means to overcome resistance, Weber concludes.